The estimated Net Worth of James R Iii Gavin is at least $2.47 Million dollars as of 3 August 2020. James Gavin owns over 14,899 units of Baxter International stock worth over $2,136,563 and over the last 22 years he sold BAX stock worth over $0. In addition, he makes $336,652 as Independent Director at Baxter International.
James has made over 9 trades of the Baxter International stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 14,899 units of BAX stock worth $568,248 on 3 August 2020.
The largest trade he's ever made was exercising 18,750 units of Baxter International stock on 28 March 2018 worth over $539,813. On average, James trades about 982 units every 36 days since 2003. As of 3 August 2020 he still owns at least 54,407 units of Baxter International stock.
You can see the complete history of James Gavin stock trades at the bottom of the page.
Dr. James R. Gavin, III M.D. Ph.D. is an Independent Director of the Company. Dr. Gavin is the Chief Medical Officer of Healing Our Village, Inc., a healthcare corporation that specializes in targeted advocacy, training, education, disease management and outreach for healthcare professionals and minority communities, having previously served as Chief Executive Officer and Chief Medical Officer from 2007 until November 2019, and Executive Vice President for Clinical Affairs from 2005 to 2007. Dr. Gavin is also Clinical Professor of Medicine and Senior Advisor of Health Affairs at Emory University, a position he has held since 2005, and Clinical Professor of Medicine at Indiana University School of Medicine in Indianapolis, a position he has held since 2008. From 2002 to 2005, Dr. Gavin was President of the Morehouse School of Medicine and from 1991 to 2002 he served as Senior Science Officer at Howard Hughes Medical Institute, a non-profit medical research organization. He previously served as a director of Amylin Pharmaceuticals, Inc. and Baxalta, before it was acquired by Shire in June 2016 and before Shire was acquired by Takeda Pharmaceutical Company in 2019.
As the Independent Director of Baxter International, the total compensation of James Gavin at Baxter International is $336,652. There are 14 executives at Baxter International getting paid more, with Jose Almeida having the highest compensation of $13,913,800.
James Gavin is 74, he's been the Independent Director of Baxter International since 2003. There are no older and 28 younger executives at Baxter International.
James's mailing address filed with the SEC is ONE BAXTER PARKWAY, , DEERFIELD, IL, 60015.
Over the last 22 years, insiders at Baxter International have traded over $966,809,165 worth of Baxter International stock and bought 178,227 units worth $6,261,495 . The most active insiders traders include Point Llc Loeb Daniel S Third, Michael F Mahoney, and Jeffrey A Craig. On average, Baxter International executives and independent directors trade stock every 37 days with the average trade being worth of $3,609,738. The most recent stock trade was executed by Jeanne K Mason on 1 March 2024, trading 64,488 units of BAX stock currently worth $2,397,019.
baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile iv solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services. the company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.
Baxter International executives and other stock owners filed with the SEC include: